Since Abcam's acquisition in 2023, founder Jonathan Milner has been making waves with his investment strategy. Discover his ...

Scientists who want a say in the future of their inventions are once again moving from academia to the C-suite ...

The potential anchor tenant, a biotech firm based in the innovation district, is being recruited by other cities.

The company behind the COVID-19 treatment drug remdesivir and the HIV antiretroviral medication Biktarvy is closing its ...

Pharmaceutical and biotech industries essentially use laboratory freeze dryers in their research. Such equipment is employed ...

The U.S. life sciences development bubble burst at the start of 2024, and it is going to take some time simply to pick up the pieces. There are already signs of recovery for the new year, though.

If the United States does not lead in emerging biotechnologies, our adversaries will, writes GOP Sen. Todd Young of Indiana.

In another sign of biopharma's waning interest in the traditional ex vivo gene therapy approach, CSL Behring is shutti | CSL ...

Consultation closed in late September on proposals to align national planning policy with the Government’s industrial strategy for key ...

Binance Labs, the crypto exchange's venture capital arm, has invested in decentralized science (DeSci) by backing the BIO ...